LifeArc Ventures

A big shoutout to LifeArc for their incredible support and partnership throughout 2024. Your dedication to driving innovation has been truly inspiring 👏 Learn more about LifeArc ➡️ https://ow.ly/v0hE50UrAMJ

2024 has been a milestone year for Closed Loop Medicine. From breakthrough clinical data to major industry partnerships, we couldn’t have done it without the hard work of our fantastic team and collaborators.   We enjoyed making our own Spotify Wrapped: Closed Loop Medicine-style to celebrate our highlights of 2024 ⬇ But, it did make us think… in this day and age, why are playlists more curated than prescriptions?   Many things in modern life are tailored precisely to our individual needs and preferences. But if anything should be tailor-made, surely it should be medicine? 💡   2025 is looking to be another exciting one as we push ahead in our mission to change the way healthcare is delivered, one milligram at a time. From all of us here at Closed Loop Medicine, Merry Christmas and a Happy New Year ⭐

Attrition among biotechs and VCs holding onto their reserve capital for existing investments may have reduced the capital available for new life sciences funding, but UK-based LifeArc Ventures believes its recent activity is indicative of a general upswing. “There is a lot of capital out there in biotech land that has been largely locked up. Companies are coming through the bottom of the curve in the current funding cycle. The stronger ones have survived and are being funded.” Read Clare Terlouw’s full interview with In Vivo’s Ashley Yeo here. LifeArc https://lnkd.in/eGdxDEev

So pleased to see this reappointment. Daniel Mahony's commitment to our sector is inspiring and his role is helping to drive real growth across UK life sciences.

Even as the year draws to a close, we’re excited to share one final announcement—the publication of a peer-reviewed study in the Journal of Medical Internet Research (JMIR Publications), detailing the outcomes of the CURE-19 trial, which demonstrated the effectiveness of our digital platform for remote blood pressure and medication monitoring. Key Outcomes: ➡️ High Engagement and Adherence: 84% of participants consistently submitted BP data over 12 weeks ➡️ Effective and Safe: Stable blood pressure control was achieved with no adverse events, validating its safety for long-term use in community settings ➡️ Positive User Experience: Participants praised the user-friendly interface Earlier this year, the PERSONAL COVID BP trial showcased the capabilities of our integrated precision care solution for hypertension treatment. As the year concludes, the CURE-19 study further underscores the success of our effective and user-friendly platform, highlighting its utility and feasibility in supporting remote disease management within healthcare systems. Read the full release here: https://lnkd.in/eimCE7AC #DigitalHealth #TechBio #PrecisionCare #Hypertension 

Looking forward to speaking at AET and catching up with some of you in San Diego!

Even as the year draws to a close, we’re excited to share one final announcement—the publication of a peer-reviewed study in the Journal of Medical Internet Research (JMIR Publications), detailing the outcomes of the CURE-19 trial, which demonstrated the effectiveness of our digital platform for remote blood pressure and medication monitoring. Key Outcomes: ➡️ High Engagement and Adherence: 84% of participants consistently submitted BP data over 12 weeks ➡️ Effective and Safe: Stable blood pressure control was achieved with no adverse events, validating its safety for long-term use in community settings ➡️ Positive User Experience: Participants praised the user-friendly interface Earlier this year, the PERSONAL COVID BP trial showcased the capabilities of our integrated precision care solution for hypertension treatment. As the year concludes, the CURE-19 study further underscores the success of our effective and user-friendly platform, highlighting its utility and feasibility in supporting remote disease management within healthcare systems. Read the full release here: https://lnkd.in/eimCE7AC #DigitalHealth #TechBio #PrecisionCare #Hypertension 

Today, our company, Fluid Biomed Inc., announces it has closed $27M USD in an oversubscribed Series A financing. For firms at our stage, the magnitude of the fundraise is the largest in Canadian medtech this year, and in the upper echelon for any emerging medical device company anywhere in recent memory. Read all about our Series A here: https://bwnews.pr/4fjnycS We're very proud of this accomplishment and it’s almost surreal to share the news. My co-founder, Dr. Alim Mitha, and myself, can attest that the entrepreneurial journey is neither easy nor straightforward. Along the ascent, business decisions are frequently informed with limited data in hand but need to be made with sufficient confidence so that the path toward success can be carved. For physicians, many factors are under our direct control to maximize the chances of a good patient outcome whereas for entrepreneurs, uncertainty abounds. I’m a neurosurgeon and have conducted brain surgery for decades, but running a startup is one of the most hardest - and rewarding - things I’ve ever done. We're grateful to all our supporters over the years who believed in our vision and mission. This financing will enable our company to do amazing things to potentially help doctors treat their patients with brain aneurysms around the world. Fluid Biomed thanks the many institutional and private investors who helped us reach this milestone, including Amplitude Ventures, IAG Capital Partners, LifeArc Ventures, ShangBay Capital, METIS Innovative, Accelerate Fund III managed by Yaletown Partners, Wharton Alumni Angels, Threshold Impact, Thin Air Labs, One Six 8 Ventures, HaloHealth, Bluesky Equities, UCeed Neuro Fund from the University of Calgary UCeed Investment Funds, and Adara Venture Capital.

Fluid Biomed Inc. is pioneering a new approach to the treatment of brain aneurysms through its unique bioabsorbable polymer-based stent technology. The ReSolv™ stent, developed by co-founders and leading academic neurosurgeons John Wong and Alim Mitha has demonstrated functional benefits in a first-in-human clinical study to treat brain aneurysms, a leading cause of stroke and disability. LifeArc Ventures continues to strengthen its focus on ground-breaking medical technology by supporting Fluid Biomed’s Series A financing alongside international investors including Amplitude Ventures, IAG Capital Partners, ShangBay Capital and METIS Innovative.